Delaware | 000-50789 | 33-0145723 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
DIGIRAD CORPORATION | |||
By: | /s/ Jeffry R. Keyes | ||
Jeffry R. Keyes Chief Financial Officer |
Exhibit No. | Description | |
99.1 | Press Release dated November 1, 2013, announcing financial results for the three and nine months ended September 30, 2013. | |
99.2 | Information Related to the use of Non-GAAP Financial Measures. |
For immediate release | For more information contact: |
November 1, 2013 | Jeffry Keyes |
Chief Financial Officer | |
858-726-1600 | |
ir@digirad.com | |
• | Included in the results for the quarter and nine months ended September 30, 2013 is a gain on the sale of assets and associated license agreement related to a surgical imaging system that was under development at Digirad, and the granting of a license related to certain existing Digirad technology. |
• | Total revenue for the third quarter of 2013 was $12.4 million, compared to $11.8 million for the same period in the prior year. DIS revenue for the third quarter of 2013 was $9.5 million, compared to $8.9 million for the same period of the prior year, and Diagnostic Imaging revenue for the third quarter of 2013 was $2.9 million, compared to $3.0 million for the same period of the prior year. |
• | Gross profit for the third quarter of 2013 was $3.8 million, or 30.8% of revenue, compared to $3.1 million, or 26.5% of revenue in the prior year quarter. |
• | Net income for the third quarter of 2013 was $2.5 million, or $0.14 net income per diluted share, compared to a net loss of $0.9 million, or $0.05 net loss per diluted share in the same period of the prior year. Adjusted net income for the 2013 third quarter, excluding expenses incurred for nonrecurring items related to restructuring activities and the gain on sale of assets and license agreement, was $1.0 million, or $0.06 adjusted net income per diluted share, compared to an adjusted net loss of $0.9 million, or $0.05 adjusted net loss per diluted share, for the same period in the prior year. |
• | Operating expenses for the third quarter of 2013 were $1.4 million, compared to $4.2 million in the same period in the prior year. Adjusted operating expenses, excluding expenses incurred for nonrecurring items related to restructuring activities and the gain on sale of assets and license agreement, for the third quarter of 2013 were $2.9 million, compared to the $4.2 million in the same period of the prior year. |
• | Cash, cash equivalents and available-for-sale securities totaled $25.9 million as of September 30, 2013. Cash, cash equivalents and available-for-sale securities totaled $22.2 million at June 30, 2013 and $27.2 million as of December 31, 2012. |
• | Total revenue for the first nine months of 2013 was $36.8 million, compared to $37.5 million for the same period in the prior year. DIS revenue for the first nine months of 2013 was $27.9 million, compared to $27.5 million for the same period of the prior year. Diagnostic Imaging revenue for the first nine months of 2013 was $8.9 million, compared to $10.0 million for the same period of the prior year. |
• | Gross profit for the first nine months of 2013 was $10.4 million, or 28.3% of revenue, compared to $10.5 million, or 28.0% of revenue in the same period of the prior year. |
• | Net loss for the first nine months of 2013 was $0.5 million, or $0.03 net loss per diluted share, compared to a net loss of $3.1 million, or $0.16 net loss per diluted share, in the same period of the prior year. Adjusted net loss for the first nine months of 2013, excluding expenses incurred for nonrecurring items related to restructuring activities and the gain on sale of assets and license agreement, was $0.4 million, or $0.02 adjusted net loss per diluted share, compared to an adjusted net loss of $3.1 million, or $0.16 adjusted net loss per diluted share, for the same period in the prior year. |
• | Operating expenses for the first nine months of 2013 were $11.0 million, compared to $13.7 million in the same period in the prior year. Adjusted operating expenses, excluding expenses incurred for |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
(in thousands, except per share amounts) | 2013 | 2012 | 2013 | 2012 | |||||||||||
(unaudited) | (unaudited) | (unaudited) | (unaudited) | ||||||||||||
Revenues: | |||||||||||||||
DIS | $ | 9,489 | $ | 8,856 | $ | 27,903 | $ | 27,522 | |||||||
Diagnostic Imaging | 2,924 | 2,961 | 8,946 | 9,975 | |||||||||||
Total revenues | 12,413 | 11,817 | 36,849 | 37,497 | |||||||||||
Cost of revenues: | |||||||||||||||
DIS | 6,916 | 6,880 | 20,920 | 20,765 | |||||||||||
Diagnostic Imaging | 1,679 | 1,808 | 5,501 | 6,250 | |||||||||||
Total cost of revenues | 8,595 | 8,688 | 26,421 | 27,015 | |||||||||||
Gross profit | 3,818 | 3,129 | 10,428 | 10,482 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 24 | 1,055 | 1,020 | 2,998 | |||||||||||
Marketing and sales | 1,042 | 1,348 | 3,287 | 4,735 | |||||||||||
General and administrative | 1,754 | 1,744 | 6,427 | 5,820 | |||||||||||
Amortization of intangible assets | 55 | 49 | 178 | 184 | |||||||||||
Restructuring charges | 79 | — | 1,693 | — | |||||||||||
Gain on sale of assets and license agreement | (1,568 | ) | — | (1,568 | ) | — | |||||||||
Total operating expenses | 1,386 | 4,196 | 11,037 | 13,737 | |||||||||||
Income (loss) from operations | 2,432 | (1,067 | ) | (609 | ) | (3,255 | ) | ||||||||
Other income (expense): | |||||||||||||||
Interest and other income, net | 13 | 28 | 52 | 82 | |||||||||||
Interest expense | (5 | ) | (2 | ) | (10 | ) | (3 | ) | |||||||
Total other income | 8 | 26 | 42 | 79 | |||||||||||
Net income (loss) before income taxes | $ | 2,440 | $ | (1,041 | ) | $ | (567 | ) | $ | (3,176 | ) | ||||
Income tax benefit | 72 | 135 | 44 | 111 | |||||||||||
Net income (loss) | $ | 2,512 | $ | (906 | ) | $ | (523 | ) | $ | (3,065 | ) | ||||
Net income (loss) per share – basic | $ | 0.14 | $ | (0.05 | ) | $ | (0.03 | ) | $ | (0.16 | ) | ||||
Net income (loss) per share – diluted | $ | 0.14 | $ | (0.05 | ) | $ | (0.03 | ) | $ | (0.16 | ) | ||||
Weighted average shares outstanding – basic | 18,328 | 19,263 | 18,890 | 19,273 | |||||||||||
Weighted average shares outstanding – diluted | 18,580 | 19,263 | 18,890 | 19,273 | |||||||||||
Adjusted Financial Data: | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
(in thousands, except per share amounts) | 2013 | 2012 | 2013 | 2012 | |||||||||||||
Total operating expenses | $ | 1,386 | $ | 4,196 | $ | 11,037 | $ | 13,737 | |||||||||
Restructuring charges(1) | (79 | ) | — | (1,693 | ) | — | |||||||||||
Gain on sale of assets and license agreement(2) | 1,568 | — | 1,568 | — | |||||||||||||
Adjusted operating expenses | $ | 2,875 | $ | 4,196 | $ | 10,912 | $ | 13,737 | |||||||||
Net income (loss) | $ | 2,512 | $ | (906 | ) | $ | (523 | ) | $ | (3,065 | ) | ||||||
Restructuring charges(1) | 79 | — | 1,693 | — | |||||||||||||
Gain on sale of assets and license agreement(2) | (1,568 | ) | — | (1,568 | ) | — | |||||||||||
Income tax items(3) | — | — | — | — | |||||||||||||
Adjusted net income (loss) | $ | 1,023 | $ | (906 | ) | $ | (398 | ) | $ | (3,065 | ) | ||||||
Net income (loss) per share - diluted | $ | 0.14 | $ | (0.05 | ) | $ | (0.03 | ) | $ | (0.16 | ) | ||||||
Restructuring charges(1)(4) | — | — | 0.09 | — | |||||||||||||
Gain on sale of assets and license agreement(2)(4) | (0.08 | ) | — | (0.08 | ) | — | |||||||||||
Income tax items(3)(4) | — | — | — | — | |||||||||||||
Adjusted net income (loss) per share - diluted(4) | $ | 0.06 | $ | (0.05 | ) | $ | (0.02 | ) | $ | (0.16 | ) | ||||||
Three Months Ended | |||||||||||||||||
(in thousands, except per share amounts) | September 30, 2013 | June 30, 2013 | March 31, 2013 | ||||||||||||||
Total operating expenses | $ | 1,386 | $ | 4,425 | $ | 5,226 | |||||||||||
Restructuring charges(1) | (79 | ) | (610 | ) | (1,004 | ) | |||||||||||
Gain on sale of assets and license agreement(2) | 1,568 | — | — | ||||||||||||||
Adjusted operating expenses | $ | 2,875 | $ | 3,815 | $ | 4,222 | |||||||||||
Net income (loss) | $ | 2,512 | $ | (616 | ) | $ | (2,419 | ) | |||||||||
Restructuring charges(1) | 79 | 610 | 1,004 | ||||||||||||||
Gain on sale of assets and license agreement(2) | (1,568 | ) | — | — | |||||||||||||
Income tax items(3) | — | — | — | ||||||||||||||
Adjusted net income (loss) | $ | 1,023 | $ | (6 | ) | $ | (1,415 | ) | |||||||||
Net income (loss) per share - diluted(4) | $ | 0.14 | $ | (0.03 | ) | $ | (0.13 | ) | |||||||||
Restructuring charges(1)(4) | — | 0.03 | 0.06 | ||||||||||||||
Gain on sale of assets and license agreement(2)(4) | (0.08 | ) | — | — | |||||||||||||
Income tax items(3)(4) | — | — | — | ||||||||||||||
Adjusted net income (loss) per share - diluted(4) | $ | 0.06 | $ | — | $ | (0.07 | ) | ||||||||||